Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Hebei University, Baoding 071002, People's Republic of China; College of Chemistry and Environmental Science, Chemical Biology Key Laboratory of Hebei Province, Hebei University, Baoding 071002, People's Republic of China.
Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Hebei University, Baoding 071002, People's Republic of China; College of Chemistry and Environmental Science, Chemical Biology Key Laboratory of Hebei Province, Hebei University, Baoding 071002, People's Republic of China.
Biomaterials. 2019 Apr;200:1-14. doi: 10.1016/j.biomaterials.2019.01.048. Epub 2019 Feb 6.
Many efforts have focused on the cancer stem cell (CSC) targeting nano delivery system, however, the anticancer therapy efficacy is relative low due to the highly drug-resistance and drug efflux. Nucleus-targeted drug delivery is a promising strategy for reverse the drug resistance and drug efflux of CSCs, but in vivo nucleus-targeted drug delivery has been challenging. Herein, we designed a mesoporous silica nanoparticle (MSN)-based nucleus-targeted system, which could directly target the CSCs and further enter the nucleus by the surface modification of anti-CD133 and thermal-triggered exposure of TAT peptides under an alternating magnetic field (AMF). The nucleus-targeted drug release ultimately leads to an exhaustive apoptosis of the CSCs through combined thermotherapy and hypoxia-activated chemotherapy. In vivo, the nucleus-targeted nano delivery system efficiently inhibits the tumor growth without notable side effects during the course of treatment. Molecular mechanism study illustrates that the system effectively eliminates the CSCs by blocking the hypoxia signaling pathway. This designed nucleus-targeted nano delivery system is expected to provide new insights for developing efficient platforms for CSC-targeted cancer therapy.
许多研究都集中在针对癌症干细胞(CSC)的靶向纳米递药系统上,然而,由于其高度的耐药性和药物外排,抗癌治疗效果相对较低。核靶向药物递送是逆转 CSCs 耐药性和药物外排的一种有前途的策略,但体内核靶向药物递送一直具有挑战性。在这里,我们设计了一种基于介孔硅纳米颗粒(MSN)的核靶向系统,它可以通过表面修饰抗 CD133 和热触发暴露 TAT 肽,在交变磁场(AMF)下直接靶向 CSCs,并进一步进入细胞核。核靶向药物释放最终通过联合热疗和缺氧激活化疗导致 CSCs 的彻底凋亡。在体内,核靶向纳米递药系统在治疗过程中能够有效抑制肿瘤生长,且没有明显的副作用。分子机制研究表明,该系统通过阻断缺氧信号通路有效地消除了 CSCs。这种设计的核靶向纳米递药系统有望为开发针对 CSC 的高效癌症治疗平台提供新的思路。